PNRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PNRG is not a good buy right now for an impatient investor. The technical trend is bullish, but price is already near resistance (~187.5) with RSI elevated and no proprietary buy signals. Meanwhile, the latest quarter shows sharp YoY deterioration (revenue, earnings, margins), and the only recent analyst initiation is a Hold with a $160 target—well below the current ~$185.9—implying limited near-term upside at this level.
Trend/Direction: Bullish. Moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200), signaling a strong uptrend.
Momentum: MACD histogram is positive (0.724) and expanding, confirming bullish momentum.
RSI: RSI_6 at 68.6 is still technically “neutral” per the label, but it’s close to overbought territory, which often precedes pullbacks or consolidation—especially near resistance.
Levels: Pivot ~176.5 (near-term trend pivot). Price (185.9) is close to R1 ~187.5; a clean breakout could target R2 ~194.3, but failure at R1 raises pullback risk toward pivot/support (S1 ~165.5).
Pattern-based odds: Similar-candlestick analog suggests a positive bias (+0.58% next day, +3.09% next week, +8.66% next month), but this is coming after a run into resistance.
Intellectia Proprietary Trading Signals
shows significant YoY contraction: revenue -31.06%, net income -52.15%, EPS -50.23%, gross margin down (36.95%, -17.37% YoY).
with RSI elevated, increasing the odds of near-term consolidation/pullback.
Latest quarter: 2025/Q3. Growth trends are negative YoY across key lines: Revenue $45.97M (-31.06% YoY), Net Income $10.56M (-52.15% YoY), EPS $4.38 (-50.23% YoY), Gross Margin 36.95% (down -17.37% YoY). Overall, fundamentals are weakening versus last year, which makes chasing the stock near resistance less attractive.
Recent trend: Limited coverage/updates in the provided data. On 2025-12-19, Freedom Capital initiated with Hold and a $160 price target. Wall Street-style view (pros/cons): Pros—acknowledges strategic operating posture/strengths. Cons—current valuation viewed as already reflecting positives while leaving investors exposed to cyclical commodity risk and execution uncertainty; the $160 target vs ~$185.9 implies downside/overvaluation at present levels. Politicians/Congress: No recent congress trading data available (no notable politician activity provided).
